Skip to main content

The Pathologist’s Perspective: The Importance of Ring Sideroblast Quantification and Evaluation in Myelodysplastic Syndromes


Faculty: Guillermo Garcia-Manero, MD, Cecilia CS Yeung, MD, FCAP, Ashley M. Eckel, MD, PhD

Original Release Date: April 28, 2022
Valid for credit through: April 28, 2023
Maximum Credits: 1.50 / AMA PRA Category 1 Credit(s)TM

Program Description
This educational satellite symposium from the United States and Canadian Academy of Pathology on the pathology of myelodysplastic syndromes with ring sideroblasts (MDS-RS) includes an engaging cross-disciplinary interview among hematopathologists and hematologic oncologists that is enhanced by media-rich infographics and a downloadable pathologist pocket guide. This session allows for deeper faculty engagement with audience members who will be able to ask questions during the session. The goal of this satellite symposium is to improve patient outcomes in MDS-RS and MDS/MPN-RS-T.

Educational Objectives
  • Define the clinical and pathologic features of MDS-RS and MDS/MPN-RS-T and their classification based on 2016 WHO criteria
  • Incorporate clinical features, peripheral blood and bone marrow findings, morphology, and cytogenetic and molecular analyses to establish a diagnosis of MDS-RS or MDS/MPN-RS-T
  • Address diagnostic challenges to guide evidence-based treatment strategies for patients with MDS-RS and MDS/MPN-RS-T

Intended Audience
This activity is designed for pathologists, hematopathologists, hematologists, hematologic oncologists, nurses, advanced practitioners (NPs/PAs), and other clinicians involved in the management of MDS patients.

Disclosures

Dr. Garcia-Manero receives research support from AbbVie Inc., APR Applied Pharma Research s.a., Astex Pharmaceuticals, Bristol Myers Squibb, Curis, Inc., Genentech, a member of the Roche Group, Gilead Sciences, Inc., and Novartis Pharmaceuticals Corporation.

Dr. Yeung receives research funding from OBI Pharma, Inc. and Sensei Biotherapeutics; is a consultant for Celgene (a Bristol Myers Squibb company), Eli Lilly and Company, Merck & Co., Inc., and Twinstrand Biosciences. She is also the owner and consultant for Molpath DX, LLC.

Dr. Eckel has purchased and sold stock within the reporting period from Johnson & Johnson Services, Inc.


CME/CE Information
Accredited Provider
Accredited by Haymarket Medical Education.

Joint Accreditation
In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE) Credit:  Designation Statement
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

AMA PRA Category 1 Credit(s)TM: Designation Statement
Physicians:
Haymarket Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pathologists: This live activity has been registered to offer credit in the American Board of Pathology’s Continuing Certification program for a maximum of 1.50 AMA PRA Category 1 CreditsTM and Improvement in Medical Practice.

Disclosure of Financial Relationships Policy
Haymarket Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Disclosure of Unlabeled Use
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this IPCE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Bristol Myers Squibb. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. If you have any questions relating to the accreditation of this activity, please contact [email protected]

Commercial Supporter
Supported by an educational grant from Bristol Myers Squibb.